


Highlights from ACR Convergence’s Late-Breaking Abstracts

FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA

Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

The Effects of IL-17A Inhibitors on the Microbiota

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Imagining a Life Free from the Pain of Ankylosing Spondylitis
- 1
- 2
- 3
- 4
- Next Page »